Concurrently, the total abundance of YAP1 slightly decreased in the combined therapy, although this change did not reach statistical significance (Fig. 6a ).
← all excerpts
Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells.
1
—
—